Arrowhead Pharmaceuticals, Inc. insider trading

Bought

—

Sold

$3.7M

6 of 8 on a 10b5-1 plan

Net

−$3.7M

Insiders

5

• Olukotun Adeoye Y

  Director

  −$173.9K

  Aug 18, 2026

  2,000 sh · $86.96

• Perry Michael S

  Director

  −$1M

  Aug 18, 2026

  11,600 sh · $87.30

• Lu Hongbo10b5-1

  Director

  −$228.3K

  May 12, 2026

  2,970 sh · $76.88

• Hamilton James C10b5-1

  Chief Medical Officer

  −$750K

  Apr 23, 2026

  10,000 sh · $75.00

• Apel Daniel Joseph10b5-1

  Chief Financial Officer

  −$224.9K

  Apr 22, 2026

  3,208 sh · $70.11

• Apel Daniel Joseph10b5-1

  Chief Financial Officer

  −$81.5K

  Apr 22, 2026

  1,157 sh · $70.45

• Apel Daniel Joseph10b5-1

  Chief Financial Officer

  −$627.9K

  Apr 22, 2026

  8,730 sh · $71.92

• Hamilton James C10b5-1

  Chief Medical Officer

  −$641.9K

  Mar 05, 2026

  10,000 sh · $64.19

Largest sale

−$6.9M of ARWR by Anzalone Christopher Richard (Chief Executive Officer · Director) on Dec 15, 2025.

From SEC's quarterly Form 3, 4 and 5 data sets: code P purchases and code S sales of common stock, by the date the trade happened. Where a fund and the people who control it each report the same block, it is counted once. Trades made in the last days of Q2 2026 but filed after it closed arrive with SEC's next quarterly release.

SEC industry classification

Pharmaceutical Preparations

Headquarters

Pasadena, CA

Incorporated in

DE

Listed on

Nasdaq

SEC Central Index Key

0000879407

Previously filed as

ARROWHEAD RESEARCH CORP

Sourced from this company's own SEC submissions record. The industry label is SEC's Standard Industrial Classification, which is more specific than the Health Care sector shown above.

The live dashboard is free to open. Alerts, watchlists, full filing history and each mover's benchmark-measured track record are Pro. Monitoring, not advice.

Open-market purchase (code P)

An insider spending their own money at market price. This is the only buy code that reliably carries signal — it is a decision, not compensation.

Grants and option exercises (codes A, M)

Scheduled compensation. Most "insider buying" headlines are really this, which is why InsiderPulse weights it at a fraction of a real purchase.

Cluster buy

Two or more different insiders buying on the open market in the same window. One executive buying can mean anything; three is much harder to explain away.

Are ARWR insiders buying or selling?

Between Mar 05, 2026 and Aug 18, 2026, 5 Arrowhead Pharmaceuticals, Inc. insiders made no open-market purchases and 8 sales worth $3.7M, a net sale of $3.7M. 6 of the sales were pre-scheduled under a Rule 10b5-1 plan.

How much ARWR stock have insiders bought and sold in the last two years?

Between Jul 01, 2024 and Jun 30, 2026, 13 Arrowhead Pharmaceuticals, Inc. insiders made no open-market purchases and 97 sales worth $49.6M. 73 of the sales were pre-scheduled under a Rule 10b5-1 plan. In the four quarters to Jun 30, 2026: no purchases and 67 sales ($37.9M). The largest sale was Anzalone Christopher Richard selling $6.9M on Dec 15, 2025.

What was the largest recent ARWR insider trade?

Perry Michael S (Director) sold $1M of ARWR stock on Aug 18, 2026 at about $87.30 a share.

When did an insider last buy ARWR shares?

No open-market purchase by a Arrowhead Pharmaceuticals, Inc. insider appears in the filings from Mar 05, 2026 to Aug 18, 2026 — every recorded open-market transaction in that period was a sale.

Where does ARWR insider trading data come from?

From the Form 4 filings Arrowhead Pharmaceuticals, Inc.'s officers, directors and 10% owners must send the SEC within two business days of a trade. Each row on this page links to its original filing on SEC EDGAR. Share grants and option exercises are kept apart from open-market purchases and sales, because only the latter cost the insider their own money.